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Ataxia with oculomotor apraxia type 2 (AOA2) is an autosomal recessive disease due to mutations in the senataxin gene,
causing progressive cerebellar ataxia with peripheral neuropathy, cerebellar atrophy, occasional oculomotor apraxia and elevated
alpha-feto-protein (AFP) serum level. We compiled a series of 67 previously reported and 58 novel ataxic patients who under-
went senataxin gene sequencing because of suspected AOA2. An AOA2 diagnosis was established for 90 patients, originating
from 15 countries worldwide, and 25 new senataxin gene mutations were found. In patients with AOA2, median AFP serum
level was 31.0 mg/l at diagnosis, which was higher than the median AFP level of AOA2 negative patients: 13.8 mg/l, P = 0.0004;
itself higher than the normal level (3.4 mg/l, range from 0.5 to 17.2 mg/l) because elevated AFP was one of the possible selection
criteria. Polyneuropathy was found in 97.5% of AOA2 patients, cerebellar atrophy in 96%, occasional oculomotor apraxia in
51%, pyramidal signs in 20.5%, head tremor in 14%, dystonia in 13.5%, strabismus in 12.3% and chorea in 9.5%. No patient
was lacking both peripheral neuropathy and cerebellar atrophy. The age at onset and presence of occasional oculomotor apraxia
were negatively correlated to the progression rate of the disease (P = 0.03 and P=0.009, respectively), whereas strabismus was
positively correlated to the progression rate (P = 0.03). An increased AFP level as well as cerebellar atrophy seem to be stable in
the course of the disease and to occur mostly at or before the onset of the disease. One of the two patients with a normal AFP
level at diagnosis had high AFP levels 4 years later, while the other had borderline levels. The probability of missing AOA2
diagnosis, in case of sequencing senataxin gene only in non-Friedreich ataxia non-ataxia-telangiectasia ataxic patients with AFP
level 57mg/l, is 0.23% and the probability for a non-Friedreich ataxia non-ataxia-telangiectasia ataxic patient to be affected
with AOA2 with AFP levels 57 mg/l is 46%. Therefore, selection of patients with an AFP level above 7mg/l for senataxin gene
sequencing is a good strategy for AOA2 diagnosis. Pyramidal signs and dystonia were more frequent and disease was less
severe with missense mutations in the helicase domain of senataxin gene than with missense mutations out of helicase domain
and deletion and nonsense mutations (P = 0.001, P = 0.008 and P=0.01, respectively). The lack of pyramidal signs in most
patients may be explained by masking due to severe motor neuropathy.
Keywords: ataxia; oculomotor apraxia; polyneuropathy; alpha-feto-protein; cerebellar atrophy
Abbreviations: AFP = alpha-feto-protein; ALS4 = amyotrophic lateral sclerosis; AOA1 = ataxia with oculomotor apraxia type 1;
AOA2 = ataxia with oculomotor apraxia type 2; ARCA = autosomal recessive cerebellar ataxia; AT = ataxia-telangiectasia;
DD = disease duration; HD = helicase domain; OMA = occasional oculomotor apraxia; SDFS = spinocerebellar degeneration
functional score corrected; SETX= Senataxin gene
Introduction
Ataxia with oculomotor apraxia type 2 (AOA2) belongs to the
autosomal recessive cerebellar ataxias (ARCAs), which are rare
and early-disabling neurodegenerative diseases, dominated by
Friedreich ataxia (Campuzano et al., 1996; Durr et al., 1996).
AOA2 is caused by mutations in the senataxin (SETX) gene
(Moreira et al., 2004). The onset of the disease usually occurs
between 12 and 20 years of age (Criscuolo et al., 2004, 2006;
Le Ber et al., 2004; Duquette et al., 2005; Anheim et al., 2008;
Tazir et al., 2009). The clinical phenotype is characterized by
progressive cerebellar ataxia, sensorimotor peripheral neuropathy,
occasional oculomotor apraxia (OMA), strabismus, chorea and/or
dystonia. Laboratory examination of AOA2 reveals prominently
elevated alpha-feto-protein (AFP) serum levels (Watanabe et al.,
1998b; Izatt et al., 2004) and, less frequently, elevated creatine
kinase (CK) serum level (Watanabe et al., 1998b). We have
recently reported slightly elevated AFP levels in healthy subjects
with SETX heterozygous mutation (Anheim et al., 2008). Brain
magnetic resonance imaging (MRI) shows diffuse cerebellar
atrophy and electroneuromyography (EMG) confirms the
peripheral neuropathy. A post-mortem study revealed a marked
loss of Purkinje cells as well as mild fibrous gliosis that was
more severe in the vermis than in the hemispheres (Criscuolo
et al., 2006).
AOA2 belongs to the group of ARCAs with OMA (Le Ber et al.,
2005, 2006) which also includes ataxia-telangiectasia (AT) due to
mutations in the AT mutated (ATM) gene (Savitsky et al., 1995;
Chun and Gatti, 2004); ataxia with oculomotor apraxia type 1
(AOA1) related to mutations in the aprataxin (APTX) gene
(Date et al., 2001; Tranchant et al., 2003; Le Ber et al., 2004;
Moreira et al., 2004) with initial signs usually occurring earlier than
AOA2; and AT-like disorder (ATLD) related to mutations in the
MRE11 gene (Stewart et al., 1999; Fernet et al., 2005). AOA2
and AT patients also share elevated AFP levels but in contrast to
AT, there is no increased sensitivity to ionizing radiation (Nahas
et al., 2007) and no susceptibility to cancer in AOA2.
Mutations in SETX have also been reported to cause dominantly
inherited juvenile amyotrophic lateral sclerosis (ALS4) (Chen et al.,
2004) and dominant tremor-ataxia (Bassuk et al., 2007). ALS4
occurs before 25 years of age and is defined by limb weakness,
severe muscle wasting, pyramidal signs, normal sensation and
a slow disease progression (Chance et al., 1998).
The predicted protein encoded by SETX, which comprises
24 exons, is 2677 amino acids long and contains at its C terminus
a classical seven-motif domain found in the superfamily 1
of helicases. Senataxin is suspected to be a DNA/RNA helicase
(Moreira et al., 2004; Ursic et al., 2004; Chen et al., 2006) and
is considered to be involved in the defence against DNA damage
(Moreira et al., 2004; Suraweera et al., 2007) and in processing
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non-coding RNAs. It has been demonstrated that senataxin is
located in the nucleus of cycling cells (Chen et al., 2006;
Suraweera et al., 2007). SETX missense mutations are mostly
located at either the N-terminal domain or the C-terminal helicase
domain (HD), supporting the fact they are both key functional
domains (Bassuk et al., 2007).
Several series of AOA2 patients have been reported but
some clinical features, such as the frequency of OMA, remain a
controversial issue (Le Ber et al., 2004; Duquette et al., 2005;
Criscuolo et al., 2006; Anheim et al., 2008; Tazir et al., 2009)
and no predictive prognosis factor has been identified. Moreover,
SETX is a large gene that is not readily amenable to routine sequen-
cing. Here, we investigated a series of 90 AOA2 patients in order to
define an efficient selection strategy for sequencing and to assess
genotype–phenotype correlations. As none of the parents had
neurological complaints, they were not extensively examined.
Patients and Methods
We retrospectively analysed the clinical, laboratory, electrophysio-
logical, imaging and molecular data of all patients who underwent
SETX sequencing in our laboratory between 2004 and 2008, because
of suspected AOA2. Sequencing of SETX was performed upon request
in case of cerebellar ataxia with elevated AFP level and/or in case of
cerebellar ataxia associated with clinical, electrophysiological and
imaging features consistent with AOA2: progressive cerebellar ataxia
occurring between 5 and 25 years of age combined with peripheral
neuropathy and/or cerebellar atrophy on MRI.
Clinical analysis
Age at onset of the disease, disease duration (DD) and age at last
examination were noted as well as gender and geographic origin.
Spinocerebellar degeneration functional score (SDFS) was used to
evaluate the disability stage from 1 to 7 (0: no functional handicap;
1: no functional handicap but signs at examination; 2: mild, able to
run, walking unlimited; 3: moderate, unable to run, limited walking
without help; 4: severe, walking with one stick; 5: walking with two
sticks; 6: unable to walk, requiring wheelchair; 7: confined to the bed).
Other assessed clinical findings included vibratory sense, deep tendon
reflexes, plantar reflexes, OMA (defined as an intermittent saccade
failure causing dissociation between the eyes and head movements
during the rotation of the head which reaches the target before the
eyes), slow and/or saccadic pursuit, hypometric saccades, strabismus,
pes cavus, chorea, dystonia, tremor and parkinsonism. Peripheral
neuropathy was defined by decreased or absent tendon reflexes,
distal lower limbs vibratory sense loss and/or motor deficit, and/or
electrophysiological evidence of nerve conduction abnormalities.
Pyramidal tract involvement was retained in case of extension
response of plantar reflexes and/or increased or diffused tendon
reflexes. Cerebellar atrophy was considered on MRI sagittal and axial
slides by both a neuroradiologist and a neurologist. The spinocerebellar
degeneration functional score corrected for DD (SDFS/DD ratio),
which is not yet validated, was used to evaluate the progression rate
of the disease. Although not precise, this ratio is easily recordable and
was the only available for the entire set of patients. AFP and CK serum
level assessment as well as EMG/nerve conduction studies and brain
MRI were performed. MRIs were performed for at least one
patient per family and were reviewed by both neuroradiologists and
neurologists. For some patients, immunoglobulin (Ig) serum level
assessment, karyotype and/or ATM sequencing were performed.
AFP level assessment in controls
Serum AFP levels were determined for control non-ataxic patients,
control non-AOA2 non-AT patients and ataxic patients with suspected
AOA2. AFP level assessment in controls was performed using
the immunoanalysis Kryptor Brahms method as established in the
Laboratoire de Biochimie Ge´ne´rale et Spe´cialise´e (LBGS) in the
University Hospital of Strasbourg, France. The dosage of AFP level in
100 healthy subjects with this method provided a median value of
3.2 mg/l with a 97.5 percentile at 7 mg/l, which was considered as
the upper limit in our study. All healthy subjects had an AFP level
between 0.5 and 15.7mg/l. We tested for AFP levels in 102 control
patients who had no cerebellar ataxia but were affected with
Parkinson’s disease (n= 37), atypical parkinsonism (n= 13),
Huntington’s disease (n= 3), dystonia (n= 1), Alzheimer’s disease
(n= 11), multiple sclerosis (n= 11), amyotrophic lateral sclerosis
(n= 2), peripheral neuropathy (n= 16) and myopathy (n= 6). These
patients were not investigated for AOA2 mutations. Moreover, a
series of 31 non-AOA2 non-AT ataxic patients (who were investigated
in another study; Anheim et al., 2009) underwent AFP level analysis.
Genetic analysis and genotype/
phenotype correlation studies
We sequenced all exons of SETX from both the forward and reverse
strands after purification of the polymerase chain reaction (PCR)
products, as reported earlier (Moreira et al., 2004) (flanking primer
sequences and PCR conditions are available on request). Sequences
were analysed using the Seqpilot software version 2.0 (JSI medisys,
Kippenheim, Germany). Quantitative SETX exon copy number analysis
was performed as described previously (Arning et al., 2008). The
AOA2 patients were divided into three groups according to the type
of mutation and/or to the location of the mutation in SETX: (i) at least
one missense mutation into the HD; (ii) at least one missense mutation
outside the HD; and (iii) no missense mutation (nonsense mutation or
frameshift insertion or deletion or large in frame deletion). The three
groups were compared regarding their clinical, electrophysiological,
imaging and biochemical features. Finally, truncating mutations in
the HD were compared to truncating mutations out of the HD.
Statistical analysis
Patients’ data were collected in a computerized database and analysed
using the statistical software package Statistical Analysis System (SAS)
for Windows, release 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Categorical variables were analysed with the 2 test and Yates’
correction or Fisher’s exact test when necessary. Non-parametric stat-
istical methods were used for analysis, as most analysed quantitative
variables could not meet the assumption of normality. Such variables are
presented as the median (Q1:25th–Q3:75th percentiles), while categor-
ical variables are presented as frequencies (percentage of patients).
We used Wilcoxon rank-sum test (two independent groups) and
Kruskal–Wallis test (more than two independent groups) for all
comparisons of quantitative variables across groups. Pearson and
Spearman correlation coefficients were computed in order to assess
the strength of the linear relationship between the two quantitative
variables.
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AFP serum level distribution was assessed using the Kernel density
estimate. For AOA2+ patients with repeated AFP assessments,
Wilcoxon signed-rank test was applied in order to perform a compari-
son between AFP values at baseline, contemporary to the diagnosis of
the disease and at the end-point at which the last assessment was
performed.
Results
Between 2004 and 2008, 125 patients underwent SETX direct
sequencing (Fig. 1). Sixty-seven were published previously
(Watanabe et al., 1998; Bomont et al., 2000; Nemeth et al.,
2000; Izatt et al., 2004; Le Ber et al., 2004; Moreira et al.,
2004; Anheim et al., 2008; Gazulla et al., 2009; Tazir
et al., 2009) and 25 new SETX mutations were identified among
the remaining patients (Table 1). One hundred patients had
elevated AFP levels and an AOA2 diagnosis was established for
90 patients (AOA2+), including two with normal AFP levels at
diagnosis (Table 2). The second mutation of a compound hetero-
zygous patient for which only one mutation was previously
reported (Anheim et al., 2008) has now been identified by copy
number determination of all SETX exons and consists of a deletion
of exons 10 to 13 (online Supplementary material). This deletion
results in an in-frame protein deletion (Table 1), explaining why
this deletion does not result in SETX RNA decay (Anheim et al.,
2008). The most typical AOA2 patients were also analysed by
SETX exon copy number determination and no deletion or duplica-
tion was identified (for example, see online Supplementary material).
AOA2+ patients: 90 patients
The main features of the AOA2+ group are presented in Tables 2
and 3. Forty-nine AOA2+ patients were male. Patients originated
from France (n= 20), Algeria (n= 20), Portugal (n= 19), Germany
(n= 6), Japan (n= 5), Pakistan (n= 5), Saudi Arabia (n= 2), Tunisia
(n= 2), Norway (n= 2), England (n= 2), Spain (n= 2), Sudan
(n= 1), Ireland (n= 1), Belgium (n= 1), Switzerland (n= 1) and
Canada (n= 1). Median age at onset was 14.0 years (Q1 = 12,
Q3 = 17) and median current age was 32.0 years (Q1 = 25,
Q3 = 40). Mean current SDFS was 4.68 1.47 after a mean DD
of 19 years, and mean SDFS/DD ratio was 0.39 0.41. Most
AOA2 patients needed unilateral or bilateral help for walking
after 20 years of DD. The few patients who were wheelchair
bound were so at a mean age of 29.9 years 3.84, after a
mean DD of 15.3 years 3.52. Peripheral neuropathy, mostly
axonal sensory motor neuropathy, was detected in 97.5% of
patients. OMA was found in 51% of cases, saccadic pursuit with-
out OMA in 4.5% and strabismus in 12.3%. Pyramidal signs were
present in 20.5% of patients. Movement disorders were not rare,
including head tremor (14%), dystonia (13.5%) and/or chorea
(9.5%). Pes cavus was noted in all 21 patients for whom this
item was documented. Cerebellar atrophy was found on MRI in
96% of patients. No AOA2 patient was lacking both peripheral
neuropathy and cerebellar atrophy. Some AOA2 patients
underwent several brain MRIs during the course of the disease,
which revealed severe cerebellar atrophy early in the course of the
disease (Fig. 2). Elevated AFP serum levels were found in 98% of
patients at the first AFP level assessment and in 99% of patients
during the course of the disease, with a median serum level of
31 mg/l. The single patient with normal AFP levels had levels at
6 mg/l (normal5 7 mg/l) after 27 years of DD and was part of a
Pakistani sibship whose other affected members had moderately
elevated AFP levels (Nemeth et al., 2000; Moreira et al., 2004).
Another patient had normal AFP levels 12 years after the onset of
the disease but AFP levels increased thereafter up to 31.5 mg/l
and 29.3mg/l, 4 and 7 years later, respectively. CK levels were
moderately elevated in three patients, normal in 20, but not deter-
mined in 67 patients. Two patients presented with hypogonado-
trophic hypogonadism: Patient 16 has previously been reported
(Gazulla et al., 2009), and Patient 44 developed amenorrhoea at
the age of 39 due to hypogonadotrophic hypogonadism with
follicle-stimulating hormone (FSH) and lutenizing hormone (LH)
at 69.6 IU/l and 41.4 IU/l, respectively.
In the AOA2+ group, age at onset was correlated with the
progression rate of the disease that was evaluated using
the SDFS/DD ratio (r= 0.23, P= 0.04). The progression rate of
the disease was negatively associated with OMA (SDFS/DD ratio
of 0.25 in patients with OMA and of 0.32 in patients without
OMA; P= 0.009) and positively associated with strabismus
[SDFS/DD median ratio of 0.38 (Q1 = 0.25, Q3 = 0.5) in case of
strabismus and of 0.26 (Q1 = 0.20, Q3 = 0.35) in patients without
strabismus; P= 0.03]. The earlier the onset, the higher was the
frequency of strabismus (P= 0.04). The progression rate and the
duration of the disease were not associated with incidence of per-
ipheral neuropathy, pyramidal signs, cerebellar atrophy or AFP
levels. AFP serum level was not correlated with age at onset of
the disease. Surprisingly, AFP level was negatively associated with
pyramidal signs (extensor plantar response; P= 0.0008): patients
with pyramidal signs had a median AFP level of 16.6 mg/l
(Q1 = 8.5, Q3 = 20.6) versus 37.7mg/l (Q1 = 24, 53.4) for patients
without pyramidal signs. AFP level was negatively associated with
strabismus 21.5mg/l (Q1 = 7, Q3 = 43.7) versus 35.5 mg/l
(Q1 = 21, Q3 = 54) and with head tremor 20mg/l (Q1 = 9,
Q3 = 45) versus 35 mg/l (Q1 = 21, Q3 = 54) (P= 0.03 and 0.02,
respectively) but was associated with neither progression rate
nor OMA.
SETX sequenced because of suspected AOA2 : N = 125
cerebellar ataxia and elevated AFP serum level
and/or cerebellar ataxia with clinical features of AOA2
AOA2 + : n = 90 AOA2 – : n = 35
AFP ↑ : n = 74
AFP nl : n = 1
AFP nd : n = 15
AFP ↑ : n = 26
AFP nl : n = 6
AFP nd : n = 3
Figure 1 Classification of the 125 patients who underwent
SETX sequencing showing the molecular diagnosis and serum
AFP levels. n= number of patients; "= elevated serum level;
nl = normal serum level; nd = not documented.
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AOA2 patients: 35 patients
In the AOA2 group, median age at onset was 12.0 years of
age (Q1 = 4, Q3 = 15) and median current age was 31.0 years
(Q1 = 22, Q3 = 50; Table 2). Mean current SDFS was
4.35 1.38 S.D after a mean DD of 18.5 years. Peripheral
neuropathy was found in 64.5% of patients, OMA in 40.6%,
saccadic pursuit without OMA in 11.8%, pyramidal signs in
25.8% and no strabismus was noted (Table 3). Movement
disorders were observed, including head tremor (15%), dystonia
(18.5%), chorea (21.4%) and parkinsonism (one patient).
Cerebellar atrophy was found on MRI in 89% of patients.
Table 1 Description of the 25 new mutations
Patient number (geographic origin) Nucleotide change (exon) Amino acid change Mutation status
3 (France) 5413C4T (10) P1805S Homozygous
6 (Ireland) 7139G4A (22) R2380Q Heterozygousa
10 (France) 2387_2390del AGAA (8) fs after K796 Homozygous
15 (France) 2659C4T (8) Q887X Homozygous
26 (France) 5264del C (8)b
del exons 10, 11, 12 and 13
fs after N1784b
V1792_L2035del
Compound
heterozygous
39 (Norway) 6792A4G (19) I2264M Homozygous
40 (Norway) 6792A4G (19) I2264M Compound
4036C4T (8) Q1346X heterozygous
41 (France) 6029A4G (13) N2010S Homozygous
44 (Saudi Arabia) 6340_6341del GA (16) fs after D2113 Homozygous
46 (Saudi Arabia) 3604del G (8) fs after I1201 Homozygous
47 (France) 7138C4G (22) R2380G Homozygous
48 (France) 2659C4T (8) Q887X Homozygous
49 (Algeria) 915G4T (6) W305C Homozygous
54 (France) 7240C4T (23) R2414X Homozygous
61 (Germany) 6590A4G (18) H2197R Homozygous
67 (France) 994C4T (6) 2966_2970del GGAAA R332W fs after Q988 Compound heterozygous
69 (France) 5249ins T (8) fs after L1750 Homozygous
89 (Belgium) del exons 6, 7 and part of 8 fs after D279 Homozygous
90 (France) 5929C4T (12)c 7000_7012del
13ins T (21)
L1977Fb
R2234_S2338del
ins C
Compound
heterozygous
94 (Switzerland) 3070_3073del GATG (8) fs after D1023 Homozygous
96 (England) 7157T4C (22) I2386T Heterozygous
117 (Portugal) 6017G4A (13) C2006Y Compound
6831_6836del AAAAAC (19) KT2278_2279del heterozygous
123 (Portugal) 5308_5311del GAGAd fs after R1769 Homozygous
126 (Portugal) 7089C4G (exon 21) F2363L Homozygous
a For Patient 6, only one of the two mutations was identified.
b Previously reported mutation in a compound heterozygous patient (Anheim et al., 2008).
c Previously reported mutations but in distinct patients, (Fogel and Perlman, 2007).
d Previously reported mutations but in distinct patients (Nicolaou et al., 2008).
del. = deletion; ins. = insertion; fs = frameshift.
Table 2 Main quantitative variables of AOA2+ and AOA2 patients
AOA2+ (Na =90) AOA2 (Na = 35) P*
Min Med Mean (SD) Max Min Med Mean (SD) Max
Age at onset 7.0 14.0 14.6 (3.4) 25.0 1.0 12.0 15.9 (16.0) 71.0 0.03
Current age 10.0 32.0 33.5 (11.7) 68.0 4.0 31.0 34.4 (17.5) 77.0 NS
Disease dur. 1.0 17.0 18.9 (11.8) 55.0 3.0 17.0 18.5 (12.9) 46.0 NS
Current SDFS 1.0 5.0 4.7 (1.5) 6.0 2.0 5.0 4.35 (1.4) 6.0 NS
Progression rateb 0.11 0.26 0.39 (0.41) 3.0 0.07 0.27 0.39 (0.35) 1.67 NS
AFPc 5.0 31.0 41.8 (34.6) 185.2 0.7 13.8 27.6 (42.3) 236.0 0.0004
a Number of patients.
b Progression rate evaluated with SDFS/DD score.
c AFP serum level.
*Wilcoxon rank-sum test.
Min = Minimum; Med = Median; SD = Standard deviation; Max = Maximum; Dur = Duration; NS = not significant.
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Elevated AFP levels were found in 81% of patients, with a median
serum level of 13.8mg/l (Q1 = 9, Q3 = 40). CK levels were ele-
vated in three patients, normal in 15 patients and not determined
in 17 patients. There was no correlation between the current SDFS
or AFP level and the DD. Age at onset was negatively associated
with pyramidal signs (P= 0.03): patients with pyramidal signs had
median onset of the disease at 24 (Q1 = 12, Q3 = 39.5) years
versus 12 (Q1 = 3, Q3 = 14) for the patients without pyramidal
signs. Friedreich ataxia was excluded in all AOA2 patients.
Three AOA2 patients had clinical and biological presentations
consistent with AT. AT was confirmed in one and is pending in
the other two. AOA1 was diagnosed in two patients, who had
AFP levels of 10mg/l and 17.8mg/l, respectively. AOA1 was
excluded in six other AOA2 patients.
Comparison of AOA2+ with AOA2
patients
The main features of the AOA2 patients (AOA2+) and of the
patients without SETX mutations (AOA2) are presented in
Tables 2 and 3. AFP levels differed significantly between
the two groups (P= 0.0004) and were higher in AOA2+
(med = 31.0, Q1 = 20.0, Q3 = 50.7 mg/l) than in AOA2
(med = 13.8, Q1 = 9.0, Q3 = 40.0mg/l) despite the fact that a
few AOA2 patients had ataxia-telangiectasia and therefore
very high AFP levels. AFP levels were more frequently elevated
in AOA2+ than in AOA2 (P= 0.003). Age at onset of the disease
was later in AOA2+ than in AOA2 (P= 0.03). There was no
difference between the AOA2+ and AOA2 groups regarding
the progression rate of the disease, the frequency of OMA nor
the frequency of pyramidal signs, which are not rare in AOA2.
Peripheral neuropathy was more frequent in AOA2+ than in
AOA2 patients (P50.0001) but cerebellar atrophy on MRI was
as frequent in both groups. Strabismus was more frequent in
AOA2+ than in AOA2 (P= 0.03) as well as pes cavus
(P= 0.03) but not head tremor, chorea or dystonia.
AFP serum level distribution
The AFP level distribution of the non-ataxic control patients, of the
AOA2 patients, and of the AOA2+ patients is shown in Fig. 3A.
The density is presented as a function of the logarithm base 10 of
AFP serum level in order to obtain Gaussian distributions.
The mean AFP level of the normal controls (3.4 4mg/l, range
from 0.5 to 17.0mg/l), non-AOA2 patients and non-AOA2
non-ataxia-telangiectasia patients from a distinct study (Anheim
et al., 2009) were identical and lower than the mean level of
AOA2 patients (27.6 42.3mg/l). The AOA2 group showed
a broad AFP level distribution ranging from normal, slightly
elevated (due to selection criteria) and markedly elevated
corresponding to confirmed and potential ataxia-telangiectasia
patients. The AOA2+ patients have a mean AFP level higher
than that for AOA2 patients (P= 0.0004). The probability
for the control patients to have an AFP 57mg/l is 89.8%. The
probability for an AOA2+ patient to have an AFP 57 mg/l
is 97.6%.
Time course of AFP serum level
By analysing the 12 AOA2+ patients with several AFP serum
assessments (Fig. 3B), we found no difference with the
Wilcoxon signed-rank test between AFP serum level measured at
the diagnosis of the disease and the AFP level at the end-point,
which corresponds to the last assessment (P= 0.66). The mean
duration between the diagnosis of ataxia and the end-point was
55.7 months. Thus, the AFP level may be considered to be stable
in the course of the symptomatic phase of AOA2. Figure 3B
indicates that among the 12 AOA2 patients, six shared a moder-
ate increase of AFP levels after the occurrence of the first signs of
the disease and then a stability of AFP levels. However, some
patients shared a slight decrease of the AFP level after the
beginning of the disease.
Senataxin gene sequencing strategy
according to AFP serum level
In our 102 non-ataxic control patients, the median AFP level was
3.4 mg/l with the 5th percentile at 1.6 mg/l and the 95th percentile
at 9 mg/l. We considered the normal AFP level to be 57mg/l
based on the study of 100 healthy individuals assessed in
the LBGS in Strasbourg, France. By using the Gaussian distri-
bution of AFP level among AOA2 and control patients, we
calculated the risk to miss an AOA2 diagnosis by sequencing
only non-Friedreich ataxia non-ataxia-telangiectasia ataxic
patients with AFP57mg/l according to the following Bayesian
probability:
P (AOA2/AFP57) = [P(AFP57/AOA2 P(AOA2)]/{[P(AFP57/
AOA2)  P(AOA2)] + [P(AFP57/non-AOA2)  P(non-AOA2)]},
non-AOA2 being the population of non-AOA2 ataxic patients.
With P(AFP57/AOA2) = 0.024, P(AOA2) = 0.08 (AOA2 preva-
lence estimated at 8% for the population of non-Friedreich
ataxia non-ataxia-telangiectasia ataxic patients (Le Ber et al.,
2004), P[(AFP57)/non-AOA2] = 0.90 and P(non-AOA2) = 0.92,
Table 3 Main qualitative variables, in percent, of AOA2+
and AOA2 patients
AOA2+
(Na =90) (%)
AOA2
(Na = 35) (%)
P*
Elevated AFP 99 81 0.003
Peripheral neuropathy 97.5 64.5 50.0001
Cerebellar atrophy 96 89 NSb
Oculomotor apraxia
(OMA)
51 40.6 NSb
Pyramidal signs 20.5 25.8 NSb
Head tremor 14 15 NSb
Dystonia 13.5 18.5 NSb
Strabismus 12.3 0 0.03
Chorea 9.5 21.4 NSb
Saccadic pursuit
without OMA
4.5 11.8 NSb
a Number of patients.
b Not statistically significant.
*2 test.
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Figure 2 Sagittal T1-weighted brain resonance magnetic imaging slices showing the stability over several years of the cerebellar
atrophy in patients affected with AOA2. Marked cerebellar atrophy in Patient 27 after 15 years (1), 19 years (2), 21 years (3), 25 years
(4) and 27 years (5) of DD (current age 39 years). Moderate cerebellar atrophy in Patient 22 after 15 years (6) and 17 years (7) of DD.
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the probability for a non-Friedreich ataxia non-ataxia-
telangiectasia ataxic patient with an AFP below 7mg/l to be
affected with AOA2 was 0.23%.
We then calculated the probability for a non-Friedreich ataxia
non-ataxia-telangiectasia ataxic patient to be affected with AOA2
in case of AFP57 mg/l using the following Bayesian ratio:
P(AOA2/AFP5 7) = [P(AFP57/AOA2) P(AOA2)]/{[P(AFP5
7/AOA2) P(AOA2)] + [P(AFP5 7/non-AOA2)P(non-AOA2)]}.
With P(AFP5 7/AOA2) = 0.976, P(AFP57/non-AOA2) = 0.1 and
P(non-AOA2) = 0.92 (Le Ber et al., 2004), this probability was
46%. Therefore, the selection of ataxic patients for SETX sequen-
cing based on AFP serum levels appeared to be an efficient
diagnosis strategy. A cut-off value of 7 mg/l or slightly less is a
very reasonable threshold above which SETX sequencing should
be recommended.
Genotype to phenotype correlation
We compared the phenotype of the AOA2+ patients according to
the type and/or the location of the mutations in SETX. Eighteen
AOA2+ patients had at least one missense mutation outside the
HD, 15 had at least one missense mutations in the HD and 54 had
only in-frame deletions or truncating mutations. Firstly, we com-
pared truncating mutations and deletions with missense mutations.
Only pyramidal signs were correlated with type of mutation, being
more frequent in patients with missense mutations than in patients
with deletion or truncating mutations (P= 0.01). There was no
difference between the two groups regarding progression rate,
dystonia, OMA, peripheral neuropathy or AFP level.
In order to further understand the increased rate of pyramidal
signs when associated with missense mutations, we divided this
group into patients with missense mutations in the HD and
patients with missense mutations outside the HD (Fig. 4). The
frequency of pyramidal signs was different in the three groups
(P= 0.001) with a high frequency for missense in the HD (57%),
compared to missense out of the HD (18.7%, P50.05) and to
deletion and truncating mutations (11.5%, P= 0.0002). With this
grouping of mutations, there were also statistically significant
differences between the three groups considering dystonia
(P= 0.01) and the progression rate of the disease measured with
the SDFS/DD ratio (P= 0.01), with a clear difference between
mutations in or out of the HD. The frequency of dystonia was
41.7% for missense mutations in the HD, 6.7% for missense
mutations out of the HD and 8.7% for deletions or truncating
mutations. The disease was more severe in cases of missense
mutations out of the HD (SDFS/DD median ratio = 0.32,
Q1 = 0.26, Q3 = 0.50) than in the HD (SDFS/DD median
ratio = 0.21, Q1 = 0.16, Q3 = 0.27) and possibly also more severe
than in the cases of deletions or truncating mutations (SDFS/DD
median ratio = 0.26, Q1 = 0.21, Q3 = 0.40). No significant differ-
ence was found considering the age at onset of the disease or the
AFP level. There was no difference between the progression rate
of AOA2 patients with truncating mutations in the HD and out
of the HD.
Discussion
Here, we report the features of 125 ataxic patients who under-
went SETX sequencing because of suspected AOA2.
AOA2+
We present correlation studies of a large cohort of 90 patients
affected with AOA2, originating from 15 different countries
worldwide, including 65 previously reported patients (Watanabe
et al., 1998a; Nemeth et al., 2000; Izatt et al., 2004; Le Ber et al.,
2004; Moreira et al., 2004; Duquette et al., 2005; Asaka
et al., 2006; Criscuolo et al., 2006; Anheim et al., 2008; Tazir
et al., 2009) as well as 23 newly identified patients whose clinical,
electrophysiological, imaging and molecular features are in
accordance with previously reported smaller series (Watanabe
et al., 1998a; Nemeth et al., 2000; Izatt et al., 2004;
Figure 3 AFP studies in patients. (A) Distribution of AFP levels
in 102 non-ataxic control patients (no ataxia), in the 35
AOA2 patients (other ataxias) and in the 90 AOA2+ patients
(AOA2). The density of points is presented in function of the
logarithm base 10 of the AFP serum level. (B) Time course of
AFP serum levels in the 12 AOA2 patients for which we had
several AFP level assessments.
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Le Ber et al., 2004; Moreira et al., 2004; Duquette et al., 2005;
Asaka et al., 2006; Criscuolo et al., 2006; Anheim et al., 2008).
AOA2 is a progressive, disabling cerebellar ataxia occurring within
the second decade, usually around 15 years of age, associated
mostly with axonal sensorimotor peripheral neuropathy (97.5%),
cerebellar atrophy (96%) and elevated AFP levels (96%). Other
signs may be encountered such as OMA (51%), pyramidal signs
(20.5%) or, less frequently, strabismus, dystonia, chorea, head
tremor and pes cavus. The mean age at onset in AOA2 is
higher than in AOA1 and AT which are 7 years and 2–3 years,
respectively (Savitsky et al., 1995; Moreira et al., 2001; Le Ber
et al., 2003; Chun and Gatti, 2004) and is similar to the mean age
at onset of Friedreich ataxia (Durr et al., 1996). However, the
range of age at onset is broader in Friedreich ataxia (from 2 to
72 years of age) than in AOA2, which is from 7 to 25 years in our
series. Interestingly, age at onset in AOA2 is correlated to the
progression rate of the disease. The course of AOA2 appears to
be less severe than in AT, AOA1 or Friedreich ataxia. Indeed, the
majority of AOA2 patients are not wheelchair bound after a mean
DD of 19 years, whereas most AT and AOA1 patients are wheel-
chair bound after a mean DD of 10 and 11 years, respectively
(Woods and Taylor, 1992; Le Ber et al., 2003). In case of ataxia
with elevated AFP levels, strabismus was very suggestive of AOA2
as it was not found at all in the group of AOA2 patients.
Moreover, the lack of both peripheral neuropathy and cere-
bellar atrophy excludes the diagnosis of AOA2 since all patients
in our series had one of the two signs. Cerebellar atrophy seems
to be an early sign of AOA2, which stabilizes after several
years of DD.
OMA was found in 50% of our patients and was negatively
correlated with the progression rate of the disease. OMA is an
optional finding in AOA2 and is less frequent than in AOA1 where
it is found in 86% of patients (Le Ber et al., 2003). OMA in AOA2
is a controversial issue. OMA was initially defined as the inability
to generate volitional horizontal saccades. Oculomotor recordings
in AOA2 may reveal increased horizontal saccade latencies and
hypometria (Le Ber et al., 2004). Other oculomotor signs may
be encountered in AOA2 including strabismus which, contrary to
OMA, is positively correlated with the progression rate of the
disease in our series. Pyramidal involvement, described in 20.5%
of our AOA2 patients, is not a rare feature although it was
only found in four out of 60 previously reported AOA2 patients
(Le Ber et al., 2004; Duquette et al., 2005; Criscuolo et al., 2006;
Anheim et al., 2008). Interestingly, pyramidal signs were found to
be negatively correlated with AFP levels. We describe one AOA2
case with hypogonadotrophic hypogonadism causing amenor-
rhoea. This contrasts the reported AOA2 case with ovarian failure
related to hypergonadotrophic hypogonadism (Lynch et al., 2007),
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therefore extending the spectrum of extraneurologic signs
in AOA2.
AOA2 patients
In contrast to the AOA2+ group, the AOA2 group appeared to
be heterogeneous. Indeed, there was no correlation in this group
between current SDFS and DD. Two AOA2 patients were sub-
sequently diagnosed with AOA1, demonstrating that elevated AFP
levels may also be found in AOA1.
AFP serum level
In the case of sequencing SETX only in ataxic patients with AFP
levels47 mg/l, the probability to miss an AOA2 diagnosis has been
found to be 0.23%. On the other hand, the probability for a non-
Friedreich ataxia non-AT ataxic patient with AFP levels47mg/l to
have AOA2 is 46%. Thus, the AFP values at or 7 mg/l appear to
be a good cut-off for selecting which patient should undergo
sequencing of SETX, given the hurdles to sequence this large
gene. In our series, AOA2+ had AFP levels higher than AOA2
patients, despite the fact that patients were partly selected
because of elevated AFP levels. In AOA2+ patients, there was
no correlation between AFP levels and progression rate or DD.
No correlation was found between AFP levels and DD despite a
mean period of nearly 5 years between the first and last measure-
ments. However, one patient presented with delayed AFP level
increase after a normal AFP level period at the beginning of the
disease. We may hypothesize that AFP levels increases in the
pre-symptomatic stage of AOA2 and then stabilize, in contrast
to AT where patients present a progressive increase of AFP
levels (Stray-Pedersen et al., 2007) and higher values, mostly
470mg/l. In case of ataxia with normal AFP levels (57 mg/l) in
the early stage of the disease, the diagnosis of AOA2 is unlikely
(0.23%) but a second assessment of AFP levels, 1 year later for
instance, is highly recommended. AFP appears to be a more useful
biomarker for AOA2 diagnosis than hypoalbuminaemia for AOA1
diagnosis since the latter occurs late in the course of the disease
(Le Ber et al., 2003). The pathophysiology of elevated AFP levels
in AOA2 remains unclear but a hepatic origin is suspected in AT
patients. The defect of polynucleotide unwinding in the AOA2
liver may be the cause of aberrant AFP gene transcription.
Whether AFP has a pathogenic role in AOA2 or is only a biochem-
ical marker remains unclear.
Genotype to phenotype correlation
Little is known about genotype/phenotype correlation in AOA2.
It has been suggested that homozygous SETX missense mutations
in the N-terminal domain or in the HD were causing similar
phenotypes to those due to deletions, nonsense and/or frameshift
mutations (Chen et al., 2006; Bassuk et al., 2007). However, we
found that missense mutations in the HD caused less severe AOA2
phenotypes than those due to missense mutations out of the HD
or those due to deletions and truncating mutations of SETX and
are more frequently associated with pyramidal signs and dystonia.
The present study highlights the fact that pyramidal signs and
dystonia are important features of AOA2. The lower frequency
of pyramidal signs in patients with truncating or missense muta-
tion out of the HD could be due to the masking of the pyramidal
signs by severe motor neuropathy. The fact that missense
mutations out of the HD are causing more severe phenotypes
than missense mutations located in the HD could be consistent
with the existence of one or more additional functional domains
in senataxin. This may include the N-terminal domain and a
conserved domain located just before the HD. However, further
studies are needed to confirm this hypothesis.
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